Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
Gary Middleton, Kristian Brock, Joshua Savage, Rhys Mant, Yvonne Summers, John Connibear, Riyaz Shah, Christian H. Ottensmeier, Paul Shaw, Siow Ming Lee, Sanjay Popat, Colin Barrie, Gloria Barone, Lucinda Billingham
Topics & Concepts
PembrolizumabMedicineDiscontinuationInternal medicineAdverse effectLung cancerOncologyPerformance statusClinical trialPhases of clinical researchSurgeryCancerImmunotherapyCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging